NCT00290979View on ClinicalTrials.gov

Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

December 31, 2004

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

insulin glulisine

Trial Locations (1)

Unknown

Sanofi-Aventis, Tokyo

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00290979 - Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter